Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMX114 Gel for Mild-to-Moderate Atopic Dermatitis
NCT04927572Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib and fingolimod in atopic dermatitis (AD) (2 arms), sponsored by Vyne Therapeutics. Primary endpoints: Atopic Dermatitis Severity Index at Day 29 and Incidence, type and severity of adverse events at Day 43. Started Oct 2021; status: completed.
02
Drugs
tofacitinibfingolimod
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04927572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927572.